To evaluate the therapeutic window, we used LGR5low and LGR5high expressing pre-B ALL tumour cells and PDXs, as well as CRC cell lines to assess their susceptibility to CD8+ T cell-mediated killing in the presence of the α-LGR5 bispecific [22]. The gene discussed is CD8A; the disease is neoplasm.